Hasanuzzaman, Johirul Lslam, A. Hossain, Rassell, M. M. Rahman, M. Rahman, A. U. Haque
{"title":"Kl67在ER+ PR+ HER2-和ERr- PRr- HER2-乳腺癌患者中的表达","authors":"Hasanuzzaman, Johirul Lslam, A. Hossain, Rassell, M. M. Rahman, M. Rahman, A. U. Haque","doi":"10.3329/jss.v20i2.43812","DOIUrl":null,"url":null,"abstract":"Background: Carcinoma of the breast is one of the most common malignancies in women worldwide. \nObjective: The current study was conducted to evaluate the role of Ki-67 as a prognosticmarker in two definite groups of breast cancer patients (ER+ve, PR+ve, HER-ve& triple negative)in Bangladesh perspective. \nMethods: Sixty nine female breast cancer patients operated at the surgical oncology departmentof National Institute of Cancer Research & Hospital were selected by non-probabilitysampling method and operated specimens were sent for immunohistochemical study of theER, PR, Her2/neu receptors and Ki-67 protein analysis. Statistical analysis was conductedusing SPSS version 17 for Windows software. P-value 0.05 or less was considered as significant. \nResult: The mean age of the patients was 46.96 years with SD of± 13.13 years. Histopathologyreports revealed that 94.2% (65/69) were suffering from duct cell carcinoma (DCC) whilelobular varieties were found in 2 cases. Majority of the patients with ER+, PR+ and Ki-67 +vestatus were between 36-50 years of age. But for Her2/neu positive cases most of patientswere above 50 years of age. In Luminal A category cancer patients 69.7% showed positiveKi-67 expression but in case of triple negative cases this percentage was 87.5%. However, thisdifference was not statistically significant. \nConclusion: Scores based upon staining of ER, PR, Her2/neu and Ki-67 collectively known asIHC4 which can be used as prognostic markers in breast cancer patients. \nJournal of Surgical Sciences (2016) Vol. 20 (2) :37-41","PeriodicalId":33248,"journal":{"name":"Journal of Surgical Sciences","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2019-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Expression of Kl67 In ER+ PR+ HER2- & ERr- PRr- HER2- Breast Cancer Patients\",\"authors\":\"Hasanuzzaman, Johirul Lslam, A. Hossain, Rassell, M. M. Rahman, M. Rahman, A. U. Haque\",\"doi\":\"10.3329/jss.v20i2.43812\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Carcinoma of the breast is one of the most common malignancies in women worldwide. \\nObjective: The current study was conducted to evaluate the role of Ki-67 as a prognosticmarker in two definite groups of breast cancer patients (ER+ve, PR+ve, HER-ve& triple negative)in Bangladesh perspective. \\nMethods: Sixty nine female breast cancer patients operated at the surgical oncology departmentof National Institute of Cancer Research & Hospital were selected by non-probabilitysampling method and operated specimens were sent for immunohistochemical study of theER, PR, Her2/neu receptors and Ki-67 protein analysis. Statistical analysis was conductedusing SPSS version 17 for Windows software. P-value 0.05 or less was considered as significant. \\nResult: The mean age of the patients was 46.96 years with SD of± 13.13 years. Histopathologyreports revealed that 94.2% (65/69) were suffering from duct cell carcinoma (DCC) whilelobular varieties were found in 2 cases. Majority of the patients with ER+, PR+ and Ki-67 +vestatus were between 36-50 years of age. But for Her2/neu positive cases most of patientswere above 50 years of age. In Luminal A category cancer patients 69.7% showed positiveKi-67 expression but in case of triple negative cases this percentage was 87.5%. However, thisdifference was not statistically significant. \\nConclusion: Scores based upon staining of ER, PR, Her2/neu and Ki-67 collectively known asIHC4 which can be used as prognostic markers in breast cancer patients. \\nJournal of Surgical Sciences (2016) Vol. 20 (2) :37-41\",\"PeriodicalId\":33248,\"journal\":{\"name\":\"Journal of Surgical Sciences\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-11-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Surgical Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3329/jss.v20i2.43812\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Surgical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3329/jss.v20i2.43812","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景:乳腺癌是全世界女性最常见的恶性肿瘤之一。目的:本研究旨在评估Ki-67在孟加拉国两组乳腺癌患者(ER+ve、PR+ve、her -ve和三阴性)中的预后指标作用。方法:采用非概率抽样方法,选取在国立肿瘤研究所肿瘤外科手术的女性乳腺癌患者69例,将手术标本送行er、PR、Her2/neu受体和Ki-67蛋白的免疫组化检测。采用SPSS version 17 for Windows软件进行统计分析。p值小于0.05为显著性。结果:患者平均年龄46.96岁,SD±13.13岁。组织病理学报告显示94.2%(65/69)为导管细胞癌(DCC), 2例为小叶细胞癌。ER+、PR+和Ki-67 +vestatus患者以36-50岁为主。但在Her2/neu阳性病例中,大多数患者年龄在50岁以上。在Luminal A类肿瘤患者中,69.7%的患者ki -67阳性表达,而在三阴性病例中,这一比例为87.5%。然而,这种差异没有统计学意义。结论:基于ER、PR、Her2/neu和Ki-67(统称asIHC4)染色的评分可作为乳腺癌患者的预后指标。外科杂志(2016)Vol. 20 (2):37-41
Expression of Kl67 In ER+ PR+ HER2- & ERr- PRr- HER2- Breast Cancer Patients
Background: Carcinoma of the breast is one of the most common malignancies in women worldwide.
Objective: The current study was conducted to evaluate the role of Ki-67 as a prognosticmarker in two definite groups of breast cancer patients (ER+ve, PR+ve, HER-ve& triple negative)in Bangladesh perspective.
Methods: Sixty nine female breast cancer patients operated at the surgical oncology departmentof National Institute of Cancer Research & Hospital were selected by non-probabilitysampling method and operated specimens were sent for immunohistochemical study of theER, PR, Her2/neu receptors and Ki-67 protein analysis. Statistical analysis was conductedusing SPSS version 17 for Windows software. P-value 0.05 or less was considered as significant.
Result: The mean age of the patients was 46.96 years with SD of± 13.13 years. Histopathologyreports revealed that 94.2% (65/69) were suffering from duct cell carcinoma (DCC) whilelobular varieties were found in 2 cases. Majority of the patients with ER+, PR+ and Ki-67 +vestatus were between 36-50 years of age. But for Her2/neu positive cases most of patientswere above 50 years of age. In Luminal A category cancer patients 69.7% showed positiveKi-67 expression but in case of triple negative cases this percentage was 87.5%. However, thisdifference was not statistically significant.
Conclusion: Scores based upon staining of ER, PR, Her2/neu and Ki-67 collectively known asIHC4 which can be used as prognostic markers in breast cancer patients.
Journal of Surgical Sciences (2016) Vol. 20 (2) :37-41